V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults
Pharmacy Times
AUGUST 12, 2025
The vaccine showed superior immune response for unique serotypes compared to PPSV23, with higher OPA titers.
2024 Compounding Immunity 
Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry
PharmaTech
JUNE 10, 2025
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. ACIP plays a foundational role in shaping immunization policy in the US. Kennedy Jr.
Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
From Pharmacy Counters to Classrooms: Building Confidence in Back-to-School Vaccinations
Pharmacy Times
AUGUST 6, 2025
Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates. Pharmacies enhance vaccine access and education, offering convenient vaccination opportunities and personalized counseling to counter hesitancy.
RSV Vaccine Uptake Remains Low Among US Adults Aged 60 Years and Older
Pharmacy Times
AUGUST 13, 2025
Arexvy was the first RSV vaccine approved by the FDA in May 2023 for adults aged 60 years and older, followed by Abrysvo, also in May 2023, and mRESVIA in May 2024; however, their indications have been updated since their initial approval.
Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits
Pharmacy Times
JUNE 20, 2025
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
Pharmacy Times
JULY 16, 2025
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
T-cell engagers to drive immuno-oncology next growth wave: GlobalData
Express Pharma
AUGUST 12, 2025
per cent compound annual growth rate from $10.4 billion in 2014 to $74 billion in 2024. The success of immune checkpoint inhibitors (ICIs) and CAR-T cell therapies fueled this initial market growth. In 2024, two landmark approvals underscored the continued evolution of the IO space.
Op-Ed: States Are Leading the Way on PBM Reform. Here’s How.
Pharmacy Times
AUGUST 1, 2025
April 9, 2024. Until Congress finds the will to act, more states should follow in their footsteps and enact similar PBM reforms that help patients access the care they need when they need it. REFERENCES Fein AJ. The top pharmacy benefit managers of 2023: market share and trends for the biggest companies—and what’s ahead. Drug Channels.
Pharmacists Bridge the Gaps in Care Transitions
Pharmacy Times
AUGUST 11, 2025
December 15, 2024. Community-based Care Transitions Program. Centers for Medicare & Medicaid Services. Accessed July 7, 2025. Medication reconciliation. Patient Safety Network. Accessed July 7, 2025. Nowosielski B. Pharmacists’ expertise can improve patient outcomes in transitions of care. Drug Topics. April 14, 2025.
FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks
Pharmacy Times
AUGUST 7, 2025
Published May 6, 2024. MMWR Recommendations and Reports. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1 4. Guideline Recommendations and Guiding Principles. Overdose Prevention. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Insmed wins FDA approval for future blockbuster Brinsupri
Pharmaceutical Technology
AUGUST 13, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
MetrioPharm gains orphan drug status from EMA for MP1032
Pharmaceutical Technology
JULY 30, 2025
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular dystrophy (DMD) in children. By GlobalData Learn more about Strategic Intelligence MP1032 targets the overactive responses of immune cells by modifying a key metabolic process within them.
New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. Deaths were reported in 5 TN and 6 R/R patients. The trial enrolled 598 patients 65 years or older with TN MCL.
Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season
Pharmacy Times
JULY 21, 2025
Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains.
COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake
Pharmacy Times
JULY 25, 2025
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
USP announces new Advanced Technologies Laboratory to accelerate and scale pharmaceutical manufacturing innovations
Pharmacy Times
JUNE 4, 2025
USP labs provide unparalleled expertise in developing quality and process standards, establishing and validating analytical methods, characterizing impurities, and synthesizing organic compounds. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies.
Pharmacists Reimagine Myeloma Care With Insights from ASCO
Pharmacy Times
JUNE 24, 2025
Updated April 2, 2024. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). Accessed June 24, 2025.
Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis
Pharmacy Times
JUNE 16, 2025
The FDA approved nemolizumab in December 2024 for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not controlled by topical prescription therapies among individuals 12 and older.
The Lifesaving Role of Continuous Glucose Monitors and Wearable Devices
Pharmacy Times
JULY 21, 2025
Related Videos Related Content Advertisement July 21st 2025 Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season Tori L. Bridging Gaps in Pharmacy Access Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
Educate Patients About Safe Medication Disposal
Pharmacy Times
JULY 18, 2025
Updated November 14, 2024. Lastly, pharmacists should consider offering mail-back envelopes at no charge to provide patients with a convenient and secure alternative to other disposal options. REFERENCES 1. The impact of pharmaceuticals released to the environment. United States Environmental Protection Agency. Accessed June 6, 2025.
Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment
Pharmacy Times
JUNE 9, 2025
2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. A comprehensive evaluation of asthma therapy within a large healthcare system. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Charlotte, NC; June 9, 2025. Global Initiative for Asthma. Accessed June 9, 2025.
Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025
Pharmacy Times
JULY 12, 2025
Since launching the service in September 2024, they’ve dispensed more than 300 boxes, with an estimated 72% acceptance rate. When patients are prescribed an opioid for the first time, the system alerts staff for a clinical consult. 1 This service can not only expand pharmacies’ clinical offerings but serves a crucial public health benefit.
You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
Pharmacy Times
JUNE 12, 2025
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma
Pharmacy Times
JUNE 25, 2025
This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models.
Fosun and Expedition make $645m licensing deal for respiratory drug
Pharmaceutical Technology
AUGUST 12, 2025
XH-S004 is an exciting compound that targets neutrophilic inflammation, an important underlying driver of a number of chronic respiratory diseases. “We Expedition chairman and CEO Yi Larson stated: “We are pleased to be working with Fosun Pharma, one of the leading pharmaceutical companies in China.
Amphastar and Anji make licence agreement for three new peptides
Pharmaceutical Technology
AUGUST 13, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
Transitions of Care Pharmacists Mitigate Readmission Rates for COPD
Pharmacy Times
JUNE 23, 2025
Updated September 10, 2024. TOC services are one of many areas where pharmacy models can improve patient outcomes, quality metrics, and hospital revenue. 4-6 Since this study’s completion, the institution has expanded its protocol with additional prescribing opportunities for TOC pharmacists and plans to expand services to non-HRRP patients.
IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma
Pharmacy Times
JULY 8, 2025
Updated November 7, 2024. August 8, 2024. Doi:10.1182/blood.2024026230 2024026230 2. MInimal Residual Disease Adapted Strategy (MIDAS). Accessed July 8, 2025. Isatuximab shows promise in enhancing PFS for patients with multiple myeloma. Pharmacy Times. Accessed July 8, 2025. Multiple myeloma. Cleveland Clinic. May 4, 2022.
FDA Approves Dupilumb for Treatment of Bullous Pemphigoid
Pharmacy Times
JUNE 20, 2025
September 11, 2024. Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. News release. Accessed June 18, 2025.
Hypertension: A Silent Killer Requiring Novel Therapies
Pharmacy Times
JULY 19, 2025
2024 ESC guidelines for the management of elevated blood pressure and hypertension. J Am Coll Cardiol. 2018;71:e127-e248. doi:10.1016/j.jacc.2017.11.006 2017.11.006 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021–3104. Eur Heart J.
Secondary Analysis Investigates Spillover Effects of Antibiotic Audit and Feedback
Pharmacy Times
JULY 16, 2025
1 The current post hoc secondary analysis was conducted from March to June 2024 and aimed to further evaluate the spillover of an audit-and-feedback intervention that targets individuals aged 65 and older on a broader population of all age groups.
Pharmacists Can Simplify the Vaccine Schedule
Pharmacy Times
JULY 22, 2025
SHOW MORE Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake. Pediatric vaccination laws vary, but pharmacists play a crucial role in educating families about vaccines like MMR, Tdap, and HPV. Before autumn approaches, start thinking about respiratory vaccines.
Moving the Needle From Vaccine Hesitancy to Vaccine Acceptance
Pharmacy Times
JULY 28, 2025
This hesitancy can lead to delayed vaccination or outright refusal, directly impacting population-level immunity and increasing the risk of widespread influenza outbreaks and associated complications. 5,6 And pharmacists and pharmacy technicians are perfectly suited to offer guidance and sound information on vaccination’s benefits.
Pharmacists Weigh Promise and Challenges of Finerenone for Patients With HFpEF
Pharmacy Times
JULY 24, 2025
New Hope: Finerenone and the FINEARTS-HF Trial The 2024 release of the FINEARTS-HF (NCT04435626) trial data has renewed attention on finerenone, which has shown promise in patients with mildly reduced or pEF. Unlike the steroidal MRAs spironolactone and eplerenone, finerenone is nonsteroidal and may offer better tolerability and adherence.
FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies
Pharmacy Times
JUNE 30, 2025
Receiving CAR T therapy can take several weeks, and though very effective against difficult-to-treat cancers, it can sometimes cause life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
Daily CBD Use at Consumer-Level Doses May Elevate Liver Enzymes, FDA-Led Trial Shows
Pharmacy Times
JULY 12, 2025
Published June 6, 2024. As CBD’s popularity surges, ensuring hepatic safety becomes a core component of patient care. REFERENCES Minnerd J. Even Low Doses of CBD May Elevate Liver Enzymes in Healthy Adults. MedPage Today. link] ClinicalTrials.gov. Published April 10, 2024. link] Tallon MJ, Child R.
FDA Approves First, Only Single-Pill Triple Combination for Treatment of Hypertension
Pharmacy Times
JUNE 9, 2025
October 19, 2024. December 2024. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. The Lancet. doi: 10.1016/S0140-6736(24)01744-6 5.
Evaluation of a Pharmacy-Delivered Oncofertility Intervention
Pharmacy Times
JUNE 11, 2025
Records from patients who received oncology treatment from Walgreens Specialty Pharmacy from December 2023 to October 2024 were analyzed to determine the percentage of patients who opted for a fertility preservation counseling session. Materials and Methods This study design was descriptive, nonexperimental, and retrospective.
The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications
Pharmacy Times
JUNE 17, 2025
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Specialty Pharmacies Can Dispense the Emotional Script to Support Patients
Pharmacy Times
JULY 23, 2025
September 2, 2024. The early data from human-centered initiatives suggest that addressing how patients feel about their treatment may be just as important as ensuring they know how to take it. REFERENCES Szczotka A. Navigating the rapid growth of specialty drugs: Opportunities, challenges, and the path ahead. Pharmacy Times. News release.
Correct Patient Misconceptions Around Biosimilars
Pharmacy Times
JUNE 27, 2025
Updated June 20, 2024. This direct engagement is crucial in building confidence in biosimilars and ensuring their appropriate utilization, contributing to more affordable and accessible health care. REFERENCES 1. Nine things to know about biosimilars and interchangeable biosimilars. Accessed May 13, 2025. Biosimilar medicines: overview.
Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug
Pharmacy Times
JULY 10, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product
Pharmacy Times
JULY 4, 2025
This single-center, retrospective, observational study included data from electronic health records and specialty pharmacies from January 1, 2023, to June 1, 2024, with specialty pharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period.
Flu Fighters: Pharmacists Partnering to Protect Communities
Pharmacy Times
AUGUST 5, 2025
During the 2023-2024 influenza season, only 44.9% The following are suggestions for pharmacists looking to utilize community connections to fight influenza. Meet Communities Where They Are Although influenza vaccines are widely available, vaccination rates remain below national goals.
Let's personalize your content